SORT1+ Technology is Effective in Many Treatment-Resistant Cance
Theratechnologies Inc.NASDAQ
Description
⋅ New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancers
Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor
Curcumin shows increased anticancer activity when conjugated to proprietary peptide
SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments
finance.yahoo.com/news/data-show-theratechnologies-sort1-technology-113010520.html